165 related articles for article (PubMed ID: 9506725)
1. Prostatic hyperplasia: an unknown feature of acromegaly.
Colao A; Marzullo P; Ferone D; Spiezia S; Cerbone G; Marinò V; Di Sarno A; Merola B; Lombardi G
J Clin Endocrinol Metab; 1998 Mar; 83(3):775-9. PubMed ID: 9506725
[TBL] [Abstract][Full Text] [Related]
2. Effect of growth hormone (GH) and insulin-like growth factor I on prostate diseases: an ultrasonographic and endocrine study in acromegaly, GH deficiency, and healthy subjects.
Colao A; Marzullo P; Spiezia S; Ferone D; Giaccio A; Cerbone G; Pivonello R; Di Somma C; Lombardi G
J Clin Endocrinol Metab; 1999 Jun; 84(6):1986-91. PubMed ID: 10372698
[TBL] [Abstract][Full Text] [Related]
3. Effect of two years of growth hormone and insulin-like growth factor-I suppression on prostate diseases in acromegalic patients.
Colao A; Marzullo P; Spiezia S; Giaccio A; Ferone D; Cerbone G; Di Sarno A; Lombardi G
J Clin Endocrinol Metab; 2000 Oct; 85(10):3754-61. PubMed ID: 11061535
[TBL] [Abstract][Full Text] [Related]
4. Prostatic disorders in acromegalic patients experience of a Brazilian center.
Corrêa LL; Balarini Lima GA; Cavallieri SA; Miranda LC; Gadelha MR
Int Braz J Urol; 2013; 39(3):393-401. PubMed ID: 23849571
[TBL] [Abstract][Full Text] [Related]
5. Prostate cancer and acromegaly.
Corrêa LL; Lima GA; Paiva HB; Silva CM; Cavallieri SA; Miranda LC; Gadelha MR
Arq Bras Endocrinol Metabol; 2009 Nov; 53(8):963-8. PubMed ID: 20126848
[TBL] [Abstract][Full Text] [Related]
6. Effect of GH and/or testosterone deficiency on the prostate: an ultrasonographic and endocrine study in GH-deficient adult patients.
Colao A; Spiezia S; Di Somma C; Marzullo P; Cerbone G; Pivonello R; Faggiano A; Lombardi G
Eur J Endocrinol; 2000 Jul; 143(1):61-9. PubMed ID: 10870032
[TBL] [Abstract][Full Text] [Related]
7. Effects of 1-year treatment with octreotide on cardiac performance in patients with acromegaly.
Colao A; Cuocolo A; Marzullo P; Nicolai E; Ferone D; Florimonte L; Salvatore M; Lombardi G
J Clin Endocrinol Metab; 1999 Jan; 84(1):17-23. PubMed ID: 9920056
[TBL] [Abstract][Full Text] [Related]
8. Is the acromegalic cardiomyopathy reversible? Effect of 5-year normalization of growth hormone and insulin-like growth factor I levels on cardiac performance.
Colao A; Cuocolo A; Marzullo P; Nicolai E; Ferone D; Della Morte AM; Pivonello R; Salvatore M; Lombardi G
J Clin Endocrinol Metab; 2001 Apr; 86(4):1551-7. PubMed ID: 11297582
[TBL] [Abstract][Full Text] [Related]
9. Cardiovascular consequences of early-onset growth hormone excess.
Colao A; Spinelli L; Cuocolo A; Spiezia S; Pivonello R; di Somma C; Bonaduce D; Salvatore M; Lombardi G
J Clin Endocrinol Metab; 2002 Jul; 87(7):3097-104. PubMed ID: 12107207
[TBL] [Abstract][Full Text] [Related]
10. Treatment of acromegaly with octreotide-LAR: extensive experience in a Brazilian institution.
Jallad RS; Musolino NR; Salgado LR; Bronstein MD
Clin Endocrinol (Oxf); 2005 Aug; 63(2):168-75. PubMed ID: 16060910
[TBL] [Abstract][Full Text] [Related]
11. Acromegaly and coronary disease: an integrated evaluation of conventional coronary risk factors and coronary calcifications detected by computed tomography.
Cannavo S; Almoto B; Cavalli G; Squadrito S; Romanello G; Vigo MT; Fiumara F; Benvenga S; Trimarchi F
J Clin Endocrinol Metab; 2006 Oct; 91(10):3766-72. PubMed ID: 16835284
[TBL] [Abstract][Full Text] [Related]
12. Ghrelin test for the assessment of GH status in successfully treated patients with acromegaly.
Pekic S; Doknic M; Miljic D; Joksimovic M; Glodic J; Djurovic M; Dieguez C; Casanueva F; Popovic V
Eur J Endocrinol; 2006 May; 154(5):659-66. PubMed ID: 16645012
[TBL] [Abstract][Full Text] [Related]
13. Octreotide as primary therapy for acromegaly.
Newman CB; Melmed S; George A; Torigian D; Duhaney M; Snyder P; Young W; Klibanski A; Molitch ME; Gagel R; Sheeler L; Cook D; Malarkey W; Jackson I; Vance ML; Barkan A; Frohman L; Kleinberg DL
J Clin Endocrinol Metab; 1998 Sep; 83(9):3034-40. PubMed ID: 9745397
[TBL] [Abstract][Full Text] [Related]
14. Severe prostate enlargement with severe lower urinary tract symptoms in poorly controlled acromegaly successfully treated with 5α-reductase inhibitors: A 15-year longitudinal case report.
Chen YC; Chen HW; Chen MT; Huang CH; Li CC; Juan YS; Ke HL
Low Urin Tract Symptoms; 2019 Apr; 11(2):O218-O220. PubMed ID: 29405593
[TBL] [Abstract][Full Text] [Related]
15. Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly.
Colao A; Ferone D; Marzullo P; Cappabianca P; Cirillo S; Boerlin V; Lancranjan I; Lombardi G
J Clin Endocrinol Metab; 2001 Jun; 86(6):2779-86. PubMed ID: 11397887
[TBL] [Abstract][Full Text] [Related]
16. Serum leptin levels in patients with acromegaly before and after correction of hypersomatotropism by trans-sphenoidal surgery.
Damjanović SS; Petakov MS; Raicević S; Micić D; Marinković J; Dieguez C; Casanueva FF; Popović V
J Clin Endocrinol Metab; 2000 Jan; 85(1):147-54. PubMed ID: 10634378
[TBL] [Abstract][Full Text] [Related]
17. Prolactin and prostate hypertrophy: a pilot observational, prospective, case-control study in men with prolactinoma.
Colao A; Vitale G; Di Sarno A; Spiezia S; Guerra E; Ciccarelli A; Lombardi G
J Clin Endocrinol Metab; 2004 Jun; 89(6):2770-5. PubMed ID: 15181056
[TBL] [Abstract][Full Text] [Related]
18. Optimizing medical therapy of acromegaly: beneficial effects of cabergoline in patients uncontrolled with long-acting release octreotide.
Jallad RS; Bronstein MD
Neuroendocrinology; 2009; 90(1):82-92. PubMed ID: 19439914
[TBL] [Abstract][Full Text] [Related]
19. Prostatic hyperplasia in acromegaly, a myth or reality: a case-control study.
Kumar S; Yadav RN; Gupta P; Gaspar BL; Kakkar N; Verma A; Parthan G; Bhansali A; Mukherjee KK; Korbonits M; Dutta P
Eur J Endocrinol; 2015 Feb; 172(2):97-106. PubMed ID: 25550351
[TBL] [Abstract][Full Text] [Related]
20. Prevalence of discordant GH and IGF-I levels in acromegalics at diagnosis, after surgical treatment and during treatment with octreotide LAR.
Machado EO; Taboada GF; Neto LV; Haute FRV; Corrêa LL; Balarini GA; Shrank Y; Goulart M; Gadelha MR
Growth Horm IGF Res; 2008 Oct; 18(5):389-393. PubMed ID: 18348909
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
